Europe’s drug innovative pipeline has reached a plateau, and is underexposed to high-growth areas such as oncology and cell & gene therapy. This paper reveals Europe’s current state of innovation, from pipeline constitution to emerging drug modalities, R&D alliances to financing trends.
